| Pasireotide versus octreotide in acromegaly: a head-to-head superiority study A Colao, MD Bronstein, P Freda, F Gu, CC Shen, M Gadelha, M Fleseriu, ... The Journal of Clinical Endocrinology & Metabolism 99 (3), 791-799, 2014 | 445 | 2014 |
| Consensus on diagnosis and management of Cushing's disease: a guideline update M Fleseriu, R Auchus, I Bancos, A Ben-Shlomo, J Bertherat, NR Biermasz, ... The lancet Diabetes & endocrinology 9 (12), 847-875, 2021 | 413 | 2021 |
| Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial MR Gadelha, MD Bronstein, T Brue, M Coculescu, M Fleseriu, ... The lancet Diabetes & endocrinology 2 (11), 875-884, 2014 | 386 | 2014 |
| The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas CA Leontiou, M Gueorguiev, J Van Der Spuy, R Quinton, F Lolli, ... The Journal of Clinical Endocrinology & Metabolism 93 (6), 2390-2401, 2008 | 355 | 2008 |
| Systemic complications of acromegaly and the impact of the current treatment landscape: an update MR Gadelha, L Kasuki, DST Lim, M Fleseriu Endocrine reviews 40 (1), 268-332, 2019 | 307 | 2019 |
| A consensus on the diagnosis and treatment of acromegaly comorbidities: an update A Giustina, A Barkan, A Beckers, N Biermasz, BMK Biller, C Boguszewski, ... The Journal of Clinical Endocrinology & Metabolism 105 (4), e937-e946, 2020 | 280 | 2020 |
| Quantitative analysis of somatostatin receptor subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas GF Taboada, RM Luque, W Bastos, RFC Guimaraes, JB Marcondes, ... European Journal of Endocrinology 156 (1), 65-74, 2007 | 266 | 2007 |
| Multidisciplinary management of acromegaly: a consensus A Giustina, G Barkhoudarian, A Beckers, A Ben-Shlomo, N Biermasz, ... Reviews in Endocrine and Metabolic Disorders 21, 667-678, 2020 | 245 | 2020 |
| A Pituitary Society update to acromegaly management guidelines M Fleseriu, BMK Biller, PU Freda, MR Gadelha, A Giustina, L Katznelson, ... Pituitary 24, 1-13, 2021 | 225 | 2021 |
| BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists CM Santos‐Silva, FRP Barbosa, GAB Lima, L Warszawski, R Fontes, ... Obesity 19 (4), 800-805, 2011 | 211 | 2011 |
| Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume … GF Taboada, RM Luque, LV Neto, EO Machado, BC Sbaffi, ... European Journal of Endocrinology 158 (3), 295-303, 2008 | 208 | 2008 |
| The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing's disease LG Perez-Rivas, M Theodoropoulou, F Ferraù, C Nusser, K Kawaguchi, ... The Journal of Clinical Endocrinology & Metabolism 100 (7), E997-E1004, 2015 | 201 | 2015 |
| Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients L Vilar, MC Freitas, LA Naves, LA Casulari, M Azevedo, R Montenegro, ... Journal of endocrinological investigation 31, 436-444, 2008 | 190 | 2008 |
| Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers LC Hernández-Ramírez, P Gabrovska, J Dénes, K Stals, G Trivellin, ... The Journal of Clinical Endocrinology & Metabolism 100 (9), E1242-E1254, 2015 | 183 | 2015 |
| Challenges in the diagnosis and management of acromegaly: a focus on comorbidities A Abreu, AP Tovar, R Castellanos, A Valenzuela, CMG Giraldo, ... Pituitary 19, 448-457, 2016 | 180 | 2016 |
| Novel pathway for somatostatin analogs in patients with acromegaly MR Gadelha, L Kasuki, M Korbonits Trends in Endocrinology & Metabolism 24 (5), 238-246, 2013 | 166 | 2013 |
| Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and … LV Neto, EO Machado, RM Luque, GF Taboada, JB Marcondes, ... The Journal of Clinical Endocrinology & Metabolism 94 (6), 1931-1937, 2009 | 153 | 2009 |
| Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial A Lacroix, F Gu, W Gallardo, R Pivonello, Y Yu, P Witek, M Boscaro, ... The Lancet Diabetes & Endocrinology 6 (1), 17-26, 2018 | 140 | 2018 |
| Giant prolactinomas: the therapeutic approach AB Moraes, C Marques dos Santos Silva, L Vieira Neto, MR Gadelha Clinical Endocrinology 79 (4), 447-456, 2013 | 132 | 2013 |
| Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open‐label, multicentre study A Colao, P Cappabianca, P Caron, E De Menis, AJ Farrall, MR Gadelha, ... Clinical endocrinology 70 (5), 757-768, 2009 | 131 | 2009 |
